1. Introduction
Type 2 diabetes results from the interaction between genetic predisposition, behavioral and environmental risk factors (1). There is strong evidence that modifiable risk factors such as obesity and physical inactivity are the main non-genetic determinants of the disease(2). New figures indicate that the number of people living with diabetes is expected to rise from 366 million to 552 million by 2030, if no urgent action is taken (3).
Impaired glucose tolerance (IGT) is an intermediate category between normal glucose tolerance and overt diabetes, and it can be identified by glucose tolerance test. Subjects with IGT have an increased risk of type 2 diabetes (4), and consequently many trials of interventions for the prevention of type 2 diabetes have focused on such individuals. By 2025, the number of people with IGT is projected to increase to 418 million, or 8.1% of the adult population (5).
Interventions to delay or even to prevent type 2 diabetes have a potential to improve the health of the population and reduce the burden of healthcare costs. The interventions assessed have been diverse and include pharmacological and lifestyle changes.
Abnormal glucose tolerance is also a well-known risk factor of incident diabetes (6). The main known predictor of incident diabetes is the presence of insulin resistance. Direct measures of insulin sensitivity can be laborious, complicated, and expensive to be applicable for routine use in the general population as a screening tool. Markers like HOMA-IR index or 2-hour post-challenge glucose levels are being used to diagnose insulin resistance.
IGT when compared to impaired fasting glucose (IFG) is a stronger risk factor in predicting the onset of diabetes (7). Diagnosing of IGT requires oral glucose tolerance test (OGTT), a test of high specificity (92%) but low sensitivity (52%) in the prediction of diabetes (8). The World Health Organization (WHO) criteria including either IFG (≥6.1 mmol/L and <7.0 mmol/L and 2-h plasma glucose concentration <11.1 mmol/L during the oral glucose tolerance test) or IGT test (<7.0 mmol/L and 2-h plasma glucose concentration ≥7.8 mmol/L and <11.1mmol/L) are used to diagnose people with IGT (9).
The clinical characteristics associated with type 2 diabetes risk include obesity and overweight, age (the risk rises steadily from puberty into geriatric years), a history of gestational diabetes, polycystic ovary syndrome, a family history of type 2 diabetes, and membership in certain high-risk minority groups: African American, Hispanic, Native American, and Asian-Pacific Islanders (6). The ADA recommends screening youth and adults with multiple risk factors for type 2 diabetes; fasting plasma glucose is the preferred first-line test (10, 11).
People with metabolic syndrome are at a high risk to develop diabetes and ischemic atherosclerotic diseases (7). Several studies have shown that metabolic syndrome is a strong predictor of incident diabetes (12-14).
The Insulin Resistance Atherosclerosis Study (IRAS) assessed a series of risk factors and identified five significant risk factors for the development of type 2 diabetes including high plasminogen activator inhibitor 1 (PAI-1), hypertension (HTN), high triglycerides (TG), low high-density lipoprotein (HDL), and IGT. The incidence of type 2 diabetes increases with the increasing number of risk factors, 5% with 0 risk factors to 50% when all 5 risk factors are present (
Every year about 5%-10% of people with IGT will develop diabetes and acquire the disease burden related to its diagnosis symptoms, need for surveillance for chronic consequences and associated costs, and increased risk of several chronic diseases (16).
The purpose of this article is to review available evidence on lifestyle and pharmacological interventionon the prevention or delay of the onset of type 2 diabetes and adapting these lessons from clinical trials to clinical practice.
2. How we can prevent type 2 diabetes?
The high economic and social costs of type 2 diabetes mellitus and its rising prevalence make a compelling case for its prevention (17). The most vulnerable groups to have diabetes are people with IFG and IGT and in the mean time they present the potent groups of preventing or delaying the progression to type 2 diabetes mellitus. These two groups are recognized as prediabetic states by the ADA (11).
3. Non pharmacological intervention
Four large prospective studies demonstrated that a treatment regimen using diet plus exercise reduces IGT progression to type 2 diabetes (18-21). Factor analysis showed that both insulin resistance and insulin secretion had a significant association with the development of diabetes, and lifestyle intervention was more effective in subjects with lower insulin resistance and higher insulin secretion (13).
3.1. Lifestyle trials - diet and physical activity
Overweight, obesity and physical inactivity are the major risk factors for developing type 2 diabetes mainly through insulin resistance. Therefore, interventions in weight reduction were shown to enhance insulin sensitivity and improve glucose tolerance in nondiabetic and diabetic subjects.
In the DaQing study, 577 subjects with IGT as defined by the WHO criteria were followed over 6 years. They were randomized into diet-only, exercise only, diet plus exercise groups, and a control group, which were associated with a 31% (
The Swedish Diabetes Prevention Study was the first individually randomized clinical trial, where 522 middle-aged overweight subjects (body mass index/BMI >25) with IGT were randomized to the control group or intervention group and followed over a mean of 3.2 years. The intervention group received individual counseling regarding diet and exercise and lost 4.2±5.1 kg
The Diabetes Prevention Program (DPP) study was a double-blind randomized controlled trial (RCT) involving a larger number of subjects, 3234 with IGT or IFG with BMI >24 kg/m2 (>22 in Asian population) followed over 2.8 years. They were randomized to standard lifestyle recommendations with placebo or with metformin or to an intensive program of lifestyle modifications (19). The incidence of developing diabetes was 4.8 cases
The Look AHEAD trial, which, like DPP, demonstrated impressive weight loss at year 1, was also followed by significant weight regain over the subsequent 3 years despite continued intensive intervention and follow-up(24).
In a recent community study in Finland, 2,797 high-risk individuals were enrolled in a diabetes prevention program designed to achieve 5–7% body weight loss. Only approximately one-third of participants were able to successfully decrease body weight by 2.5% (25).
From above mention studies it is obvious that successful weight reduction alone is not sufficient to prevent diabetes in a large percentage of individuals. The main issues is that it is difficult to maintain weight without an intervention program.
The key components of lifestyle interventions in clinical practice based on the studies analyzed by Burnet
The overall goal for diabetes prevention is to reach and maintain an active, healthy weight with a tendency toward a hypocaloric diet. Evidence supports limiting total calories and fat (25% of caloric intake) and increasing dietary fiber (20 to 30 g/day). Essential skills include understanding portion sizes and reading food labels (37).
4. Pharmacological interventions
Weight regain is a characteristic feature of most weight reduction programs, irrespective of the type of dietary intervention and similarly, weight loss achieved with pharmacological intervention is associated with major weight regain once medication is discontinued.
As shown above, lifestyle modification is the best strategy to prevent the progression of metabolic risk factors and to prevent cardiovascular events and the onset of diabetes. However, pharmacological trials have shown important results.
4.1. Metformin
Metformin (MF) 850 mg was used in one arm of the DPP study along with standard lifestyle recommendations. Subjects in this study had a decrease in their calorie intake by a mean of 296±23 kcal compared to 249±27 kcal in the placebo group; their average fat intake decreased by 0.8±0.2% in both the MF and the placebo group (
The DPP demonstrated a 31% reduction in IGT conversion to type 2 diabetes in subjects receiving metformin, 850 mg twice daily (15,21).
4.2. α-Glucosidase inhibitors
Both acarbose (STOP-NIDDM) (26) and voglibose (27) have been shown to decrease conversion of IGT to type 2 diabetes. Although this preventive effect initially was believed to result from inhibition of carbohydrate absorption, α-glucosidases augment incretin hormone secretion; thus, enhanced b-cell function could, in part, explain their beneficial effects on glucose homeostasis (28). Subjects on acarbose were by 25% less likely to develop diabetes compared to placebo at the end of 1 year, and this continued to the end of the study. The reduced risk was present even after adjusting for change in weight, age, sex, or BMI (
4.3.Thiazolidinediones
Thiazolidinediones (TZD) are insulin sensitizers that act by facilitating glucose transport into the muscle and by acting on Perioxisome Proliferator Activated Receptor (PPAR)-γ receptors in the adipose cells to shift fat from visceral to less active subcutaneous fat compartment thus reducing insulin resistance. The TRIPOD was a single-center, placebo-controlled randomized controlled trials, which enrolled Mexican-American women with prior gestational diabetes mellitus (GDM) randomized to either placebo or troglitazone 400 mg/day. The mean annual incidence of diabetes was 5.4% in the troglitazone group
In another study ACT NOW, pioglitazone (45 mg/day) decreased by 72% (P <0.00001) IGT conversion to type 2 diabetes (31).
4.4.Orlistat
Orlistat is another pharmacological agent used in the prevention of diabetes. Orlistat is a weight-reduction agent that inhibits the activity of intestinal lipase and thus decreases the amount of fat (triglycerides) absorbed. After 4 years' treatment, the cumulative incidence of diabetes was 9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 37.3% (P = 0.0032). Exploratory analyses indicated that the preventive effect was explained by the difference in subjects with IGT. Mean weight loss after 4 years was significantly greater with orlistat (5.8 vs. 3.0 kg with placebo; P < 0.001) and similar between orlistat recipients with impaired (5.7 kg) or normal glucose tolerance (NGT) (5.8 kg) at baseline. A second analysis in which the baseline weights of subjects who dropped out of the study was carried forward also demonstrated greater weight loss in the orlistat group (3.6 vs. 1.4 kg; P < 0.001)(32).
4.5. GLP-1 analogs
Liraglutide and exenatide are GLP-1 receptor agonists that mimic the actions of GLP-1 and are resistant to dipeptidyl peptidase-4 degradation. GLP-1 analogs represent a logical therapeutic intervention for treatment of IGT. Moreover, the stimulatory effect of GLP-1 and GLP-1 analogs on insulin secretion is glucose dependent, minimizing risk for hypoglycemia (33). Once-daily liraglutide also reduces body weight and decreases IGT conversion to type 2 diabetes in obese nondiabetic subjects (34).
4.6. Angiotensin converting enzyme inhibitor (ACEI)/angiotensinogen receptor blocker (ARB)
In addition to the beneficial effects on hypertension, the kidneys and the heart, both ACEI and ARBs have been shown to improve insulin sensitivity and glycemic control. Therapy with ACEI, like captopril and ramipril, and ARBs, like losartan and valsartan has been shown to reduce the incidence of new-onset diabetes anywhere by 14% to 34% (18). Although the exact mechanism how these agents reduce the incidence of diabetes is not known, it is well established that ACEI increases glucose uptake in skeletal muscle through increased synthesis of GLUT- 4 transporter protein secondary to up-regulation of insulin receptor substrate 1 (IRS 1) activity, enhanced bradykinin and nitric oxide (NO) activity (35).
4.7. Statins
The West of Scotland Coronary Prevention Study (WOSCOPS) examined the effect of pravastatin on cardiovascular (CV) events and observed that these pharmacological interventions were associated with a 30% reduction in the incidence of diabetes as secondary outcome (36). Therapeutic agents used to treat other coexisting conditions like hypertension and dyslipidemia with agents like ACEI/ARB/statins can also help with the prevention of diabetes and CV disease (15).
5. Conclusions and recommendations
From the trials discussed it was shown that both non pharmacological and pharmacological intervention can reduce the risk of type 2 diabetes in people with IGT, but lifestyle intervention seems to be more effective than pharmacological interventions. Lifestyle intervention, which aims to reduce obesity and increase physical activity, helps in addressing directly these risk factors. In the mean time lifestyle interventions incur fewer and less serious side effects than drug treatment. Like in pharmacological interventions, lifestyle interventions may not be permanent and advice on diet and exercise needs to be regularly reinforced by professional staff. For pharmacological interventions, adverse effects need to be fully understood to enable the potential harms and benefits to be assessed.
In lifestyle intervention, clinicians should recommend behavior changes for asymptomatic patients at a high risk of diabetes such as IGT. High-risk patients can be identified through clinical characteristics augmented with careful screening by fasting glucose. Although the diabetes prevention trials used intensive strategies for effecting lifestyle change, clinicians can translate key elements from those strategies into brief, office-based counseling on physical activity and dietary change. As it was proved by different trials in clinical practice, lifestyle changes should be made better through structured programs. These programs, proved to be successful in clinical practices from different countries, should emphasize goal setting, practice and motivational interviewing with patients, education and skills development, self-monitoring, behavior change (cognitive restructuring), physical activity, problem solving, stress and stimulus control, the importance of social support, and the utilization of community resources.
Multidisciplinary care teams consisting of nurses, clinicians, dietitians, psychologist physiotherapists and health educators may provide more intensive counseling and increase the motivation to continue and achieve the targets. Other forms of awareness rising as printed materials or if possible interactive computer programs in offices can reinforce counseling efforts. Implementing diabetes prevention will require significant changes for both patients and clinicians. Every health system that provide these special services need to educate clinicians in training and in practice about the potential benefits of diabetes prevention. Appropriate programs on the prevention or delay of type 2 diabetes have to be culturally adaptive for office-based counseling considering the better results planned to achieve. Besides office bases counseling with patients and family members, successful diabetes prevention efforts through lifestyle changes will likely require involvement broader societal entities such as schools, communities and workplaces.
References
- 1.
Neel J. V Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? Am J Hum genet1962 14 353 62 - 2.
Manson J. E Rimm E. B Stampfer M. J et al Physical activity and incidence of non insulin dependent diabetes mellitus in women. 1991 338 774 8 - 3.
International Diabetes Federation Diabetes Atlas, 5rd ed. Brussels: International DiabetesFederation;2011 - 4.
The DECODE Study Group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet1999 354 617 21 - 5.
International Diabetes Federation Diabetes Atlas, 3rd ed. Brussels: International DiabetesFederation;2006 - 6.
Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern MedStern M. P Williams K Haffner S. M 2002 136 575 81 - 7.
Emini-sadiku M Car N Metelko Z Bajraktari G Morina N Devolli D Prevention or delay of type 2 diabetes by pharmacological or lifestyle interventions DiabetologiaCroatica2008 37 1 - 8.
OrioJr F Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J ClinEndocrinolMetab2005 90 6072 6 - 9.
World Health Organization Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. P art1: diagnosis and classification of diabetes mellitus.Geneva: World Health Organization;1999 - 10.
American Diabetes Association Type 2 diabetes in children and adolescen ts. Diabetes Care2000 23 381 9 - 11.
American Diabetes Association Screening for type 2 diabetes. 2004 S11 3 - 12.
Meigs J. B Williams K Sullivan L. M et al Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. 2004 27 1417 26 - 13.
, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 2004;53:1773-81. ,Hanley AJ ,Festa A Jr RBD ’Agostino - 14.
Brewer Jr, HB Cleeman JI, etal.Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. CirculationGrundy S. M 2004 109 433 8 - 15.
Babu A Fogelfeld L Metabolic syndrome and prediabetes Dis Mon2006 - 16.
DREAM Trial Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet2006 368 1096 105 - 17.
Zimmet P Alberti K. G Shaw J Global and societal implications of the diabetes epidemic. 2001 414 782 7 - 18.
Tuomilehto J Lindstrom J Eriksson J. G et al Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med2001 344 1343 50 - 19.
Knowler W. C Barrett-connor E Fowler S. E et al Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med2002 346 393 403 - 20.
Eriksson K. F Lindgärde F Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmö feasibility study. 1991 34 891 898 - 21.
Pan X. R Li G. W Hu Y. H et al Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. 1997 20 537 544 - 22.
Li G Hu Y Yang W et al Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res ClinPract2002 58 193 200 - 23.
Lindstrom J Eriksson J. G Valle T. T et al Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial J Am SocNephrol2003 S108 13 - 24.
Pi-sunyer X Blackburn G Brancati F. L et al Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. 2007 30 1374 1383 - 25.
Saaristo T Moilanen L Korpi-hyövälti E et al Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D) 2010 33 2146 2151 - 26.
Laakso M; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. LancetChiasson J. L Josse R. G Gomis R Hanefeld M Karasik A 2002 359 2072 2077 - 27.
Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. LancetKawamori R Tajima N Iwamoto Y Kashiwagi A Shimamoto K 2009 373 1607 1614 - 28.
.Type2 Diabetes Can Be Prevented With Early Pharmacological Intervention. Diabetes Care 34(Suppl. 2):S202-S209, 2011 ,De Fronzo R Abdul-Ghani M - 29.
Buchanan T. A Xiang A. H Peters R. K et al Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. 2002 51 2796 803 - 30.
Weiss R Taksali S. E Tamborlane W. V et al Predictors of changes in glucose tolerance status in obese youth. 2005 28 902 9 - 31.
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J MedDe Fronzo R. A Tripathy D Schwenke D. C et al 2011 364 1104 1115 - 32.
Torgerson J. S Hauptman J Boldrin M. N et al XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. 2004 27 155 61 - 33.
Triplitt C Defronzo R. A Exenatide: first in class incretin mimetic for the treatment of type 2 diabetes mellitus Exp Rev EndocirnolMetab2006 1 329 341 - 34.
Astrup A Rössner S Van Gaal L et al Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet2009 374 1606 1616 - 35.
Ramipril increases the protein level of skeletal muscle IRS- 1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats. NaunynSchmiedebergs Arch PharmacolKreutzfeldt J Raasch W Klein H. H 2000 362 1 6 - 36.
The WOSCOPS Study Group West of Scotland Coronary Prevention Study: implications for clinical practice. The WOSCOPS Study Group. Eur Heart J1996 17 163 4 - 37.
Burnet D. L Elliott L. D Quinn M. T Plaut A. J Schwartz M. A Chin M. H Preventing diabetes in the clinical setting J Gen Intern Med2006 21 84 93